Statistics

Total Visits

Views
FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial46

File Visits

Downloads
VERSION EDITOR.pdf11

Select a period of time:

Number of views in the range

Views
FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial26

Number of downloads in the range

Downloads
VERSION EDITOR.pdf1

Views

Views
October 20240
November 20240
December 20240
January 20256
February 20251
March 202519
April 20250
Download CSV file
 untranslated
 untranslated

Number of downloads in the period of time

  • Downloads
  • October 2024
    0
  • November 2024
    0
  • December 2024
    1
  • January 2025
    0
  • February 2025
    0
  • March 2025
    0
  • April 2025
    0
  • Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore19
Italy2
United States2
United Arab Emirates2
Germany1
 

Top countries by downloads

Downloads
Germany1
 

Top cities views

Views
Los Angeles1
 

Top cities by downloads

Downloads